Asosiy kontentga oʻtish
AkademIndex

Mahsulotlar

Ishlab chiquvchilar uchun

AkademBaseEkotizim uchun ochiq API

Chronic Myeloid Leukemia Treatments

32 ta ish

  1. THE SIGNIFICANCE OF DRIVER GENE MUTATIONS JAK2, CALR, AND MPL IN CHRONIC MYELOPROLIFERATIVE DISEASES

    Beknur Bobir ugli Giyosov, Kodirjon Tukhtaboevich Boboev, Feruz Asatullaevich Daminov

    MaqolaMyeloproliferative Neoplasms: Diagnosis and TreatmentZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  2. Level and Serum Metabolism of Homocysteine in Chronic Myeloid Leukemia Patients: A Literature Review

    K. S. Samarina, Yuliana Yurevna Assesorova, I. V. Berger

    MaqolaChronic Myeloid Leukemia TreatmentsClinical oncohematology20260 iqtibos
    ABI

  3. Durable Disease Control in Disseminated Primary Splenic Leiomyosarcoma Treated With Sequential Gemcitabine–Docetaxel and Pazopanib Therapy: A Case Report

    Saida Kurbanova, Biloliddin Sharobiddinov, Oqila Abdusattorova +1

    MaqolaGastrointestinal Tumor Research and TreatmentCureus20260 iqtibos
    ABI

  4. Possibilities of Cytogenetic Studies in Acute Myeloid Leukemia (Literature Review)

    Assessorova Yuliana Yurevna, Sadikova Shirin Erimmatovna, Madatov Kurbonboy Aminboevich

    MaqolaAcute Myeloid Leukemia ResearchInternational Journal of Medical Science and Public Health Research20260 iqtibos
    ABI

  5. Method Development And Validation For Estimation Of Related Substances In Selpercatinib Bulk Dosage Form By Rp-Hplc Technique

    Mr. Suraj P. Rajurkar, Mr. Salman Ahmad Khan, Mr. Shivprasad Sanjay Dhage +5

    MaqolaChronic Myeloid Leukemia TreatmentsInternational Journal of Drug Delivery Technology20260 iqtibos
    ABI

  6. PHARMACOLOGICAL PROPERTIES OF TYROSINE KINASE INHIBITORS: CURRENT PERSPECTIVES

    Kamola Anvarjon kizi Almirzayeva

    MaqolaChronic Myeloid Leukemia TreatmentsZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  7. PHARMACOLOGICAL PROPERTIES OF TYROSINE KINASE INHIBITORS: CURRENT PERSPECTIVES

    Kamola Anvarjon kizi Almirzayeva

    MaqolaChronic Myeloid Leukemia TreatmentsZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI